What states are actually doing about compounded GLP-1s and peptides
Most coverage of peptide legality argues about federal law. The enforcement that has actually closed businesses and pulled products in the last two years has been at the state level, and it has not used drug scheduling to do it.
The two enforcement theories, and why the distinction matters to you#
If you are trying to work out whether something is "legal," scheduling is the wrong thing to look at. Here is what is actually being used:
- Consumer protection (attorney general). The claim is not that the compound is a controlled substance — it is that selling it was an unfair or deceptive trade practice, often paired with unlicensed practice of pharmacy. Connecticut has run this play four times. The remedies are injunctions, monetary penalties, and occasionally personal liability for executives.
- Licensure and possession (pharmacy board). The claim is that a licensee possessed or used something it was not permitted to, or that no valid prescriber relationship existed. This is faster and blunter: Ohio suspends licences without a prior hearing when it finds evidence of immediate and serious harm.
Neither requires a legislature to act, which is why this has moved much faster than the federal Category 2 process our categories explainer covers.
Verified state actions#
16 actions across 9 states, each opened and quoted at the primary source.
The Alabama State Board of Medical Examiners considered a petition brought on behalf of the Alabama Board of Pharmacy and ruled that "(1) Alabama-licensed physicians are not permitted to compound or dispense a drug using non-prescription quality ingredients. (2) Alabama-licensed physicians are required to purchase prescription products and ingredients only from an entity permitted by the Alabama State Board of Pharmacy. (3) Alabama-licensed physicians are required to comply with USP standards when compounding GLP-1 products." The petition's factual background states that semaglutide is being advertised to physician offices in salt forms and research-grade powder that are "NOT approved by the FDA nor are they evaluated for safety".
Why it matters: The route is the interesting part and it is why this belongs on the page. A pharmacy board cannot discipline a physician, so Alabama's reached office compounding by asking the medical board to rule on it instead. Any state where the two boards will cooperate like this can close the physician-office gap without new legislation. It is also a direct answer to the research-grade powder question: buying from an unpermitted supplier is, in Alabama, a licensing matter for the doctor.
How we verified it: Read from the ruling itself (41pp) on 2026-09-13. We had recorded it as August 2024; the document states the Board considered the petition on 18 July 2024 and gives no later adoption date, so it is dated to that.
On 13 March 2025 the Commission issued an immediate Limited Stop Service against Aequita Pharmacy LLC of Kirkland, which compounds GLP-1s including semaglutide and tirzepatide, alleging it failed to implement a commission-approved plan of correction. The deficiencies named are "allowing untrained and unqualified staff to perform sterile compounding", failing to properly supervise staff, and "not adhering to sterile compounding procedures designed to ensure product integrity and patient safety". The pharmacy "cannot compound and cannot dispense, deliver, or distribute compounded products in Washington state until the Limited Stop Service is resolved".
Why it matters: This is the closest thing on this page to a compounder actually being stopped, and it is worth reading for what it is about: sterile-compounding practice, staffing and supervision — not a finding that compounded GLP-1s are unlawful. The product category is context; the failures are the reason. It is also interim rather than final. The pharmacy had 28 days to request a hearing, so a reader should not take it as a settled finding of wrongdoing.
How we verified it: Read at the Department of Health newsroom on 2026-09-13. We had it recorded as "reported as March 2025"; the notice is dated 13 March 2025 and names the pharmacy, which our note did not.
Attorney General Kwame Raoul's office published an alert headed "UPDATED CONSUMER ALERT" on 3 January 2025, warning that many sellers advertising Ozempic, Wegovy, Mounjaro and Zepbound are instead offering unapproved versions. It states the FDA does not review compounded drugs for safety, quality or effectiveness, flags formulations "not evaluated or tested in humans, such as drops, skin patches and nasal sprays", and warns against sellers encouraging people to "reconstitute GLP-1 medications, break apart Mounjaro and Zepbound pens or vials to use as separate doses, or to water down doses". The office advises getting a prescription from a trusted provider and filling it at an appropriately licensed pharmacy.
Why it matters: These are consumer warnings, not enforcement. No licence was suspended and no order was issued, and reading them as a state cracking down on 503A compounding would be wrong — both alerts aim at sellers operating without a prescription, at "research only" material, and at formulations no regulator has evaluated. A pharmacy dispensing patient-specific compounded semaglutide against a valid prescription is not what either office is describing. The dose-splitting warning is the one we have not seen elsewhere: breaking a pen into separate doses or watering one down is a cost-saving practice this office names directly.
How we verified it: Read at the Attorney General's own site on 2026-09-13. We had it recorded as "January 2025"; the alert is dated 3 January 2025. It is labelled an update and gives no original date, so we date it to the version published.
Attorney General Alan Wilson's office published "CONSUMER ALERT: Attorney General Alan Wilson warns consumers to be cautious when purchasing unapproved and compounded weight loss medications" on 3 January 2025. It states that "the FDA does not review any compounded drugs for safety, quality, or effectiveness", that sellers are promoting formulations that "may never have been tested in humans at all, such as pill, sublingual drops, lozenges or films taken under the tongue, topical skin patches, and nasal sprays", and that products from unscrupulous sellers "may be counterfeit and pose serious health risks".
Why it matters: These are consumer warnings, not enforcement. No licence was suspended and no order was issued, and reading them as a state cracking down on 503A compounding would be wrong — both alerts aim at sellers operating without a prescription, at "research only" material, and at formulations no regulator has evaluated. A pharmacy dispensing patient-specific compounded semaglutide against a valid prescription is not what either office is describing. The formulation list is the most useful part for a buyer: drops, lozenges, films, patches and sprays are the shapes this office is pointing at.
How we verified it: Read at the Attorney General's own site on 2026-09-13. We had it recorded as "January 2025"; the alert is dated 3 January 2025.
The rewritten compounding rules at 16 CCR 1735 et seq took effect 1 October 2025. They define an "essentially a copy" preparation as one containing the same active ingredients as a commercially available product, excluding any preparation where a change was made for an identified individual patient producing "a clinically significant difference, as verified and documented by the pharmacist." A compounder may only prepare such a copy where the product is on the ASHP or FDA shortage list at the time of compounding or within the previous 60 days, or where "the pharmacist verifies and documents that the compounding produces a clinically significant difference for the medical need of an identified individual patient", with that documentation kept readily retrievable. Separately, every API used in a sterile preparation must come from an FDA-registered facility and arrive with a Certificate of Analysis carrying the compendial name, the grade of the material and the applicable compendial designations, evaluated before use.
Why it matters: This is the mechanism most likely to matter to a California buyer of compounded semaglutide or tirzepatide. Where a commercial product exists and is not in shortage, the personalisation has to be real, patient-specific and written down — a dose or additive chosen to sidestep the copy rule rather than to treat the person is what the documentation requirement is aimed at.
How we verified it: Read from the Board of Pharmacy Order of Adoption (45pp, dated 17 June 2025) on 2026-09-13; the 1 October 2025 effective date is from the Board's own approved-regulations listing. One part of the claim we had recorded did NOT check out and is not published: that the COA must name the manufacturer of the active ingredient rather than the distributor. The adopted text specifies compendial name, grade and compendial designations, requires the API itself to come from an FDA-registered facility, and does not use the word "distributor" anywhere in 45 pages.
The Board's published suspension list runs from 17 January 2025 through 4 August 2026 and is dominated by med spas, aesthetics clinics, IV-hydration providers and men's-health and testosterone clinics. Suspensions issue without a prior hearing on clear and convincing evidence of a danger of immediate and serious harm. The Board's own February 2026 newsletter puts the count at "more than 30" as of that date.
Why it matters: This is the most aggressive licensing-board program we found anywhere, and it targets exactly the clinic model that sells peptides alongside aesthetics.
Signed 22 May 2026, effective 1 August 2026, enacting La. R.S. 37:23.5. It bars state licensing boards from prohibiting prescribers and pharmacies from providing peptides — but only where the pharmacy is already in compliance with 21 U.S.C. 353a. An earlier draft tied the protection to a peptide not being on the FDA Category 2 list; the sponsor's own floor amendment deleted that language before passage.
Why it matters: The compliance condition is the whole story. BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon have no USP monograph, are not components of approved drugs, and are not on the federal bulks list — so they cannot satisfy 353a, and the shield never engages for them. Louisiana did not deregulate peptides; it protected conduct that was already lawful. The law also binds only Louisiana licensing boards, not the FDA, the DOJ, or a plaintiff.
The most directly peptide-targeted state pronouncement we found. It also requires active ingredient to come from an establishment registered with the FDA and licensed both in Washington and in its own resident state.
Why it matters: Names research peptides explicitly rather than reaching them by implication, and adds a dual-licensure requirement most suppliers cannot meet.
The platform must halt US sales, deploy a monitoring system, and remove listings within five days. Penalty of $300,000, suspended after $30,000. Announced alongside a settlement with a Connecticut med spa over advertising and prescribing non-FDA-approved compounded semaglutide and tirzepatide.
Why it matters: The relief reaches nationwide, not just Connecticut — one state's consumer-protection settlement changed what buyers anywhere could order from that seller.
The Board states that no clinic should order, possess, or administer any drug labelled for research purposes only, that doing so violates state and federal law "regardless if the patient 'consents'," and that such stock must be disposed of immediately with patients advised to stop. Inspectors specifically named retatrutide and cagrilintide. The same document says BPC-157 and other Category 2 and 3 bulk substances cannot be compounded, and that adding bacteriostatic saline to an unfinished product is itself compounding and must meet compounding rules.
Why it matters: The clearest statement any regulator has published that the RUO label does not create a lawful route for a clinic, and that a consent form does not fix it.
A full repeal-and-replace of the compounding regulations at 16 CCR 1735-1738. Section 1736.9(d) requires the certificate of analysis to give the name and address of the manufacturer, not merely a distributor, and an ingredient without it may not be used. Section 1736.9(e) bars components labelled not for human use. The "essentially a copy" test is stricter than the federal one: the pharmacist must independently verify and document a clinically significant, patient-specific difference.
Why it matters: The manufacturer-naming rule attacks the exact opacity that lets unregistered material enter the supply chain. Note the scope limit — the certificate rule applies to sterile compounding.
A $300,000 judgment, suspended after payment of $18,500, with the company's chief executive personally liable for the full amount if the agreement is breached.
Why it matters: Personal liability for an executive is unusual in this space and signals how the state viewed the conduct.
Products labelled research use only, or made by establishments not registered with the FDA, may not be used for compounding in any circumstance. Existing retatrutide and cagrilintide inventory must be disposed of immediately. Semaglutide and tirzepatide salt forms are treated as different active ingredients than the approved drugs and are prohibited. Ohio adds a state-specific requirement that all active ingredient be purchased from Ohio-licensed distributors.
Why it matters: Names the two compounds currently driving the gray market and forecloses them at the pharmacy level, not just the clinic level.
Filed under the Connecticut Unfair Trade Practices Act plus unlicensed practice of pharmacy, with a civil investigative demand to an online marketplace. Warning letters went to weight-loss clinics and med spas stating that advertising and selling these compounded medications may violate CUTPA, and singling out providers who claim the drugs are FDA-approved or are "generic" versions of the brand products.
Why it matters: The theory here is consumer protection and unlicensed pharmacy — not drug scheduling. That is the template other states are most likely to copy.
Three boards jointly stated that identifying a physician or advanced practice clinician as a medical director, on staff, or available is insufficient to establish the valid practitioner-patient relationship required before prescribed drugs are administered. The prescriber must personally evaluate and diagnose the patient and make the treatment recommendation.
Why it matters: This goes directly at the figurehead-prescriber structure used by many direct-to-consumer platforms and med spas.
Nevada's administrative code places human growth hormone on Schedule III outright and lists chorionic gonadotropin within its Schedule III anabolic steroid entries. The rule dates to 1982 as amended through 2017 — longstanding background law, not a recent development. Nevada statute also directs the Board to schedule any product used to enhance athletic performance, muscle mass, strength or weight without medical necessity, language broad enough on its face to reach growth-hormone secretagogues, though we found no evidence the Board has applied it to them.
Why it matters: The clearest example that state drug law and federal drug law diverge on peptide hormones. Federally, HGH is not scheduled.
What to watch next: The ALEC model bill#
A model policy titled the American Peptide Access Act was finalised by the American Legislative Exchange Council on 12 August 2026. Its title clause is verbatim identical to Louisiana's, but it is structurally different in the way that matters: it defines a peptide as a polymer of fewer than 40 amino acids, expressly names BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax and Epitalon — precisely the seven that are not on the federal bulks list — and contains no reference to 21 U.S.C. 353a, no reference to Category 2, and no federal-compliance condition at all.
Read the model policy →
What we confirmed is not the case#
Negative findings are worth as much as positive ones here, because the peptide internet is full of confident claims in both directions.
| Finding | Basis |
|---|---|
| No state we checked schedules any GLP-1 | Semaglutide, tirzepatide, retatrutide and cagrilintide are handled as prescription or unapproved drugs, not controlled substances. |
| No state we checked schedules research peptides | BPC-157, ipamorelin, CJC-1295 and MK-677 appear in no schedule we read. Restriction happens through pharmacy-board possession and compounding rules instead. |
| Illinois and Florida do not schedule peptide hormones | We read both states' Schedule III text in full and found no growth hormone, somatropin, or chorionic gonadotropin entry. |
| Ohio does not require an in-person visit for compounded GLP-1s or peptides | Ohio's in-person-visit authority is tied to Schedule II controlled substances, which these are not. Ohio also expressly permits asynchronous telehealth, subject to meeting the in-person standard of care. |
Reported but not yet verified#
These come from a named law-firm survey whose underlying citations we could not open at the primary source. We list them so you know where to look, and we are not treating them as established until we have read the documents ourselves.
| State | Reported action |
|---|---|
| Oregon, Kansas, Kentucky, West Virginia, New Jersey | Pharmacy board statements on semaglutide compounding, reported across 2023 to 2025. |
What this means if you are buying#
- The RUO label protects the seller, not you. Ohio's position is that a clinic possessing RUO product is in violation regardless of consent. If a provider is administering something labelled research use only, the legal exposure is theirs and the medical exposure is yours.
- "A doctor oversees it" may mean nothing. Three Ohio boards jointly said a named medical director who never evaluates you does not create a prescriber relationship. Ask who actually reviewed your intake, by name.
- Retatrutide and cagrilintide are the current flashpoint. A state board has ordered existing inventory destroyed. Anyone still selling them is operating against explicit written guidance.
- Your state may differ. We verified three states deeply and could not survey the rest. Your state pharmacy board's website is the authoritative source, and it is usually searchable.
Regulatory news#
PCAC voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List on narrow margins (BPC-157 8–6); DSIP was voted down. FDA staff had recommended against inclusion, and the committee is advisory — the FDA's final call is still pending.
Our Legal-Status Tracker, updated →The most-watched peptide of the reclassification clears its first regulatory hurdle. Category 2 removal is separate from 503A compounding eligibility — two different tracks.
The two-track explainer →The reversal of the 2023 restrictions began here. The FDA's formal updated list remains unpublished; every row of our tracker updates the day it drops.
The Legal-Status Tracker →All tracked news → · Subscribe to this beat (RSS) · Fed by a daily automated scan; entries publish only after primary-source verification.
Common questions#
Are GLP-1 drugs or research peptides controlled substances?#
In no state we checked. Semaglutide, tirzepatide, retatrutide and cagrilintide are regulated as prescription or unapproved drugs, not controlled substances, and research peptides such as BPC-157 appear in no schedule we read. Nevada is the notable exception on a related point: it schedules human growth hormone and hCG as Schedule III, which federal law does not.
Is it legal for a clinic to buy peptides labelled "research use only"?#
The Ohio Board of Pharmacy has stated plainly that no clinic should order, possess or administer any drug labelled for research purposes only, that doing so violates state and federal law regardless of whether the patient consents, and that such stock must be disposed of immediately. A signed consent form does not create a lawful route.
Which state is most active on compounded GLP-1 enforcement?#
Connecticut has the most active attorney general program, running lawsuits and settlements under its unfair trade practices act, including one 2026 settlement that stopped a marketplace selling into the entire United States. Ohio has the most aggressive licensing board program, having summarily suspended 54 clinics and med spas since January 2025.
Regulatory journalism, not legal or medical advice, and not a substitute for checking your own state's rules. Enforcement in this area is moving quickly; each item is dated and linked to its source, and corrections land in our changelog.